Management attributes 2025 progress to the ‘Three-S’ strategy (Simplify, Streamline, Strengthen), which successfully stabilized the store brand business and recovered infant formula service levels above 90%.
Performance was driven by significant market share gains in U.S. OTC and European brands, despite a ‘soft’ market environment characterized by reduced consumer consumption and trade-down to smaller units.
The company secured over $100 million in new distribution and competitive takeaways, which management views as a reversal of years of share decline.
Operational results were supported by $320 million in benefits from Project Energize and supply chain reinvention, offsetting gross profit flow-through headwinds.
Management is pivoting the portfolio toward ‘CORE Perrigo’ by divesting non-core assets like Dermacosmetics to focus on high-scale consumer health categories.
The current market weakness is viewed as 90% transitory, caused by a lack of historical price increases and a weak cough and cold season rather than structural shifts.
2026 is designated as a transition year, with guidance assuming continued negative OTC consumption in the first half followed by a second-half recovery driven by innovation and distribution gains.
A significant temporary headwind of approximately $0.60 per share is expected in 2026 due to plant under-absorption stemming from lower 2025 sales volumes.
The company is launching a new two-year operational enhancement program targeting $80 million to $100 million in annualized savings, including a 7% global workforce reduction.
Strategic reviews for the Infant Formula and Oral Care businesses remain ongoing to assess plant optimization, partnerships, or potential divestment options.
Management expects to share a long-term growth algorithm for CORE Perrigo later in 2026, focusing on cash flow and margin expansion as conditions normalize in 2027.
A $1.3 billion non-cash goodwill impairment charge was recorded in 2025 to align historical acquisition costs with current market valuations.
Management warned of a potential additional non-cash impairment charge of up to $350 million in Q1 2026 due to the reallocation of goodwill into new reporting segments.
The Dermacosmetics divestiture is expected to close in Q2 2026, with proceeds earmarked for debt reduction to manage the 4x net leverage ratio.
Infant Formula continues to face structural challenges, including intensified competition and slower demand recovery, impacting overall corporate margins.
